{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148112","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.591015+00:00","generated_at":"2026-06-01T08:16:25.984341+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options","bullets":["Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.","Reducing workforce by ~53% (18 employees); expected ~16 FTE remaining; cash costs ~$1.2M in Q2 2024.","Continuing IK-595 (MEK-RAF glue) Phase 1; >80% pERK inhibition at 4h, >60% at 24h; dose escalation ongoing.","Cash, equivalents and marketable securities $157.3M as of March 31, 2024.","Board authorized exploration of strategic alternatives including acquisition, merger, sale, or partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148112","json":"https://secwatch.observer/filing/0001193125-24-148112.json","markdown":"https://secwatch.observer/filing/0001193125-24-148112.md","text":"https://secwatch.observer/filing/0001193125-24-148112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/0001193125-24-148112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/d817758d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:16:25.984341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18e1d87b5cdd6fa87de25fbf600d4d1482d5cd92","claim":"ImageneBio, Inc. announced a restructuring with charges of approximately $1.2 million in cash expenditures affecting company-wide (clinical programs IK-930 and IK-595) (approximately 53%).","evidence_excerpt":"the Restructuring Plan during the three months ended June 30, 2024 related to employee severance and related termination benefits, which are expected to result in approximately $1.2 million in cash expenditures. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/0001193125-24-148112-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.2 million in cash expenditures"},{"label":"Affected area","value":"company-wide (clinical programs IK-930 and IK-595)"},{"label":"Headcount","value":"approximately 53%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}